Cargando…
Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
The reduction of survival motor neuron (SMN) protein causes spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disease. Nusinersen is an antisense oligonucleotide, approved by the FDA, which specifically binds to the repressor within SMN2 exon 7 to enhance exon 7 inclusion and augme...
Autor principal: | Li, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105407/ https://www.ncbi.nlm.nih.gov/pubmed/32233169 http://dx.doi.org/10.3349/ymj.2020.61.4.273 |
Ejemplares similares
-
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018) -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021) -
Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020) -
Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020) -
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)